WILLIAM WONG to Antineoplastic Agents
This is a "connection" page, showing publications WILLIAM WONG has written about Antineoplastic Agents.
Connection Strength
0.472
-
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. Oncologist. 2020 03; 25(3):e512-e519.
Score: 0.322
-
Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time. J Oncol Pract. 2018 05; 14(5):e280-e294.
Score: 0.072
-
Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. J Oncol Pract. 2016 06; 12(6):e710-23.
Score: 0.063
-
Assessing Dietary Intake in Childhood Cancer Survivors: Food Frequency Questionnaire Versus 24-Hour Diet Recalls. J Pediatr Gastroenterol Nutr. 2015 Oct; 61(4):499-502.
Score: 0.015